Telratolimod
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Telratolimod
- Molecular weight
- 593.9
- Structure (SMILES)
- CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21
- 3m 052
- 3M-052
- medi 9197
- Medi 9197
- Medi-9197
- medi9197
- Medi9197
- MEDI9197
- telratolimod
- Telratolimod
- telratolimod [INN]
- Telratolimod [WHO-DD]
- telratolimod inn
- telratolimod who dd
- CAS registry numbers
- 1359993-59-1
- ChEMBL ID
- CHEMBL4297631
- InChIKey
- RRTPWQXEERTRRK-UHFFFAOYSA-N
- PubChem compound IDs
- 56833311
- FDA ingredient codes (UNII)
- 16598XQ2BT
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -imod
- Mechanism
- Toll-like receptor 7 agonist
- Action type
- Agonist
- Target
- Toll-like receptor 7
- Protein identifier
- Q9NYK1
- Mechanism
- Toll-like receptor 8 agonist
- Action type
- Agonist
- Target
- Toll-like receptor 8
- Protein identifier
- Q9NR97
- Mechanism
- Toll-like receptor 7 agonist
- Action type
- Agonist
- Target
- Toll-like receptor 7
- Mechanism
- Toll-like receptor 8 agonist
- Action type
- Agonist
- Target
- Toll-like receptor 8
- Condition
- HIV Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000180
- Subject identifier
- D015658
- Condition
- HIV Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Lymphoma, T-Cell, Cutaneous
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002913
- Subject identifier
- D016410
- Condition
- Zika Virus Infection
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0018661
- Subject identifier
- D000071243
- Condition identifier
- EFO_0000180
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0000607
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Highest recorded phase
- 1
- NCT02556463
- NCT04177355
- NCT05781542
- NCT05903339
- NCT05983874
- NCT06267872
- NCT05828095
- NCT06334393
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 95.06
- Calculated partition coefficient (ALogP)
- 9.1
- Calculated partition coefficient (XLogP)
- 11.9
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 25
- Heavy atoms
- 43
- Molecular formula
- C36H59N5O2
- Monoisotopic mass
- 593.46687614
- Natural product
- No
- Recorded assays
- 4
- Active assays
- 0
- Adjuvants, Immunologic
Related records
Trials (13)
- A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum
- A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine Candidate
- A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV
- A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
- A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted
- Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
- Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV
- Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV
- Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults
- Pancoronavirus Vaccine Study in Healthy Adults
- Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
- Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected
- Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy
In development for (3)
- HIV infectious disease Phase 1
- Primary cutaneous T-cell non-Hodgkin lymphoma Phase 1
- Zika virus infectious disease Phase 1